Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: Long-term follow-up of the STI571 0102 and 0109 trials

Haematologica

Volumn 94, Issue 5, 2009, Pages 743-744

  Silver, Richard T ^a   Cortes, Jorge ^b   Waltzman, Roger ^c   Mone, Manisha ^c   Kantarjian, Hagop ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic myeloid leukemia; CML AP; CML BC; Imatinib

Indexed keywords

IMATINIB;

BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 66049150292     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.006999     Document Type: Letter

References (6)

1. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:753-774 (Pubitemid 38969143)
2. Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, et al. The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009 DOI: 10.3324/haematol. 13529
3. Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 2008;93: 1792-1796
4. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937.
5. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539 (Pubitemid 34534519)
6. Silver RT, Talpaz M, Sawyers CL, Druker BJ, Hochhaus A, Schiffer CA, et al. Four years of follow-up of 1027 patients with late chronic Phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large Phase II Trials. Blood 2004;104:23.